Our results indicate that colon cancer cells, both EGFR+ (MC-38) and EGFR− (CT-26), are responsive to 8 h in vitro treatment with rTBL-1, presenting LC50 values of 23.50 and 30.01 μg/mL, respectively (p = 0.063). The gene discussed is EGFR; the disease is malignant colon neoplasm.